Drug Profile
Urtoxazumab
Alternative Names: Anti-verotoxin of O-157; TMA-15Latest Information Update: 24 May 2010
Price :
$50
*
At a glance
- Originator Teijin Pharma
- Class Antidiarrhoeals; Monoclonal antibodies
- Mechanism of Action Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haemolytic uraemic syndrome
Most Recent Events
- 16 Oct 2006 Data presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2006) have been added to the adverse events and pharmacokinetics sections
- 12 Nov 2004 Phase-I clinical trials in Haemolytic uraemic syndrome in Japan (IV)
- 12 Nov 2004 Phase-I clinical trials in Haemolytic uraemic syndrome in USA (IV)